{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:07:57Z","timestamp":1790644077794,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["#1136418"],"award-info":[{"award-number":["#1136418"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["#1159261"],"award-info":[{"award-number":["#1159261"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["#1176922"],"award-info":[{"award-number":["#1176922"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["#1142363"],"award-info":[{"award-number":["#1142363"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["#1146128"],"award-info":[{"award-number":["#1146128"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ajog.2020.09.014","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T22:01:21Z","timestamp":1600207281000},"page":"S1157-S1170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"S","title":["Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia"],"prefix":"10.1016","volume":"226","author":[{"given":"Stephen","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u2019uhevaha J.","family":"Kaitu\u2019u-Lino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne","family":"Hastie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Brownfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cluver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2020.09.014_bib1","doi-asserted-by":"crossref","first-page":"f6564","DOI":"10.1136\/bmj.f6564","article-title":"Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis","volume":"347","author":"Ananth","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2020.09.014_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejogrb.2013.05.005","article-title":"Global and regional estimates of preeclampsia and eclampsia: a systematic review","volume":"170","author":"Abalos","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2020.09.014_bib3","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0140-6736(15)00070-7","article-title":"Pre-eclampsia","volume":"387","author":"Mol","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2020.09.014_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.116.003497","article-title":"Preeclampsia and future cardiovascular health: a systematic review and meta-analysis","volume":"10","author":"Wu","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ajog.2020.09.014_bib5","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/CIRCULATIONAHA.118.038080","article-title":"Preeclampsia and cardiovascular disease in a large UK pregnancy cohort of linked electronic health records: a CALIBER study","volume":"140","author":"Leon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ajog.2020.09.014_bib6","first-page":"CD004659","article-title":"Antiplatelet agents for preventing pre-eclampsia and its complications","volume":"2019","author":"Duley","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2020.09.014_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2020.09.014_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0140-6736(19)32973-3","article-title":"Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (aspirin): a randomised, double-blind, placebo-controlled trial","volume":"395","author":"Hoffman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2020.09.014_bib9","first-page":"CD001059","article-title":"Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems","volume":"10","author":"Hofmeyr","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2020.09.014_bib10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0140-6736(18)31818-X","article-title":"Prepregnancy and early pregnancy calcium supplementation among women at high risk of pre-eclampsia: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"393","author":"Hofmeyr","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2020.09.014_bib11","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/0140-6736(93)90889-O","article-title":"Pre-eclampsia: more than pregnancy-induced hypertension","volume":"341","author":"Roberts","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2020.09.014_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.placenta.2009.02.009","article-title":"Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy","volume":"30","author":"Burton","year":"2009","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2020.09.014_bib13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ajog.2020.09.014_bib14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2020.09.014_bib15","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJMoa055352","article-title":"Soluble endoglin and other circulating antiangiogenic factors in preeclampsia","volume":"355","author":"Levine","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.ajog.2020.09.014_bib16","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.placenta.2011.12.006","article-title":"Review: does size matter? Placental debris and the pathophysiology of pre-eclampsia","volume":"33","author":"Redman","year":"2012","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2020.09.014_bib17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/0141076814562718","article-title":"The environment and disease: association or causation? 1965","volume":"108","author":"Hill","year":"2015","journal-title":"J\u00a0R Soc Med"},{"key":"10.1016\/j.ajog.2020.09.014_bib18","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1471-0528.2012.03311.x","article-title":"Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis","volume":"119","author":"Kleinrouweler","year":"2012","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2020.09.014_bib19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/HYPERTENSIONAHA.117.10182","article-title":"Meta-analysis and systematic review to assess the role of soluble fms-like tyrosine kinase-1 and placenta growth factor ratio in prediction of preeclampsia: the SaPPPhirE study","volume":"71","author":"Agrawal","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.09.014_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/HYPERTENSIONAHA.107.087700","article-title":"Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia","volume":"50","author":"Rana","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.09.014_bib21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.116.08620","article-title":"Prediction of preeclampsia using the soluble fms-like tyrosine kinase 1 to placental growth factor ratio: a prospective cohort study of unselected nulliparous women","volume":"69","author":"Sovio","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.09.014_bib22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/AOG.0b013e3181e10ebd","article-title":"Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia","volume":"116","author":"Costantine","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.014_bib23","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1073\/pnas.1011293108","article-title":"Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model","volume":"108","author":"Kumasawa","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ajog.2020.09.014_bib24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1189\/jlb.1112603","article-title":"A\u00a0leading role for the immune system in the pathophysiology of preeclampsia","volume":"94","author":"Laresgoiti-Servitje","year":"2013","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.ajog.2020.09.014_bib25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0002-9378(99)70239-5","article-title":"Preeclampsia: an excessive maternal inflammatory response to pregnancy","volume":"180","author":"Redman","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.014_bib26","first-page":"412","article-title":"Tumor necrosis factor-alpha, interleukin-6, and interleukin-10 levels are altered in preeclampsia: a systematic review and meta-analysis","volume":"70","author":"Lau","year":"2013","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.ajog.2020.09.014_bib27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1161\/01.HYP.0000141085.98320.01","article-title":"Oxidative stress and preeclampsia: rationale for antioxidant clinical trials","volume":"44","author":"Raijmakers","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.09.014_bib28","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S0002-9378(98)70550-2","article-title":"Lipid peroxide and vitamin E patterns in pregnant women with different types of hypertension in pregnancy","volume":"178","author":"Gratac\u00f3s","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.014_bib29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0143-4004(96)90021-1","article-title":"Lipid peroxidation and antioxidants in normal and pre-eclamptic pregnancies","volume":"17","author":"Poranen","year":"1996","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2020.09.014_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s004180100301","article-title":"Enzyme histochemically detectable NAD(P)H oxidase in human placental trophoblasts: normal, preeclamptic, and fetal growth restriction-complicated pregnancy","volume":"116","author":"Matsubara","year":"2001","journal-title":"Histochem Cell Biol"},{"key":"10.1016\/j.ajog.2020.09.014_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0301-2115(99)00023-8","article-title":"Lipid peroxidation and antioxidants in preeclampsia","volume":"85","author":"Madazli","year":"1999","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2020.09.014_bib32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12872-015-0124-z","article-title":"Endothelial cell control of thrombosis","volume":"15","author":"Yau","year":"2015","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ajog.2020.09.014_bib33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0002-9378(82)90730-X","article-title":"Plasma antithrombin III activity: an aid in the diagnosis of preeclampsia-eclampsia","volume":"142","author":"Weiner","year":"1982","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.014_bib34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/0002-9378(91)90435-T","article-title":"High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone","volume":"165","author":"Taylor","year":"1991","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.014_bib35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ahj.2018.12.007","article-title":"Comparative effectiveness and safety of statins as a class and of specific statins\u00a0for primary prevention of cardiovascular disease: a systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants","volume":"210","author":"Yebyo","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.ajog.2020.09.014_bib36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1161\/HYPERTENSIONAHA.115.05445","article-title":"Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia","volume":"66","author":"Brownfoot","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.09.014_bib37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.preghy.2020.03.004","article-title":"Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction","volume":"20","author":"de Alwis","year":"2020","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.ajog.2020.09.014_bib38","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/HYPERTENSIONAHA.111.175919","article-title":"Role of complement component C1q in the onset of preeclampsia in mice","volume":"58","author":"Singh","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.09.014_bib39","doi-asserted-by":"crossref","first-page":"366.e1","DOI":"10.1016\/j.ajog.2011.06.083","article-title":"Effects of pravastatin on mediators of vascular function in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia","volume":"205","author":"Fox","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.014_bib40","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1161\/HYPERTENSIONAHA.111.00226","article-title":"Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension","volume":"61","author":"Bauer","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.09.014_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120147","article-title":"Pravastatin therapy during preeclampsia prevents long-term adverse health effects in mice","volume":"3","author":"Garrett","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ajog.2020.09.014_bib42","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1161\/HYPERTENSIONAHA.119.13219","article-title":"Statins reverse postpartum cardiovascular dysfunction in a rat model of preeclampsia","volume":"75","author":"Kr\u00e4ker","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.09.014_bib43","doi-asserted-by":"crossref","first-page":"720.e1","DOI":"10.1016\/j.ajog.2015.12.038","article-title":"Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial","volume":"214","author":"Costantine","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.014_bib44","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1172\/JCI86957","article-title":"Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy","volume":"126","author":"Lefkou","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ajog.2020.09.014_bib45","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/1471-0528.16013","article-title":"Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial","volume":"127","author":"Ahmed","year":"2020","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2020.09.014_bib46","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S1701-2163(15)30565-X","article-title":"The fetal safety of statins: a systematic review and meta-analysis","volume":"36","author":"Zarek","year":"2014","journal-title":"J\u00a0Obstet Gynaecol Can"},{"key":"10.1016\/j.ajog.2020.09.014_bib47","doi-asserted-by":"crossref","first-page":"373.e1","DOI":"10.1016\/j.ajog.2013.05.038","article-title":"Transplacental transfer and distribution of pravastatin","volume":"209","author":"Nanovskaya","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.014_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196387","article-title":"Statins impact primary embryonic mouse neural stem cell survival, cell death, and fate through distinct mechanisms","volume":"13","author":"Carson","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2020.09.014_bib49","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1161\/HYPERTENSIONAHA.116.08408","article-title":"Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction","volume":"69","author":"Onda","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.09.014_bib50","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejogrb.2018.05.004","article-title":"Magnesium sulfate versus esomeprazole impact on the neonates of preeclamptic rats","volume":"225","author":"Shafik","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2020.09.014_bib51","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1002689","article-title":"Use of proton-pump inhibitors in early pregnancy and the risk of\u00a0birth defects","volume":"363","author":"Pasternak","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2020.09.014_bib52","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10620-011-1940-3","article-title":"The safety of fetal exposure to proton-pump inhibitors during pregnancy","volume":"57","author":"Matok","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ajog.2020.09.014_bib53","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-0889","article-title":"Acid-suppressive drug use during pregnancy and the risk of childhood asthma: a meta-analysis","volume":"141","author":"Lai","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.ajog.2020.09.014_bib54","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/HYPERTENSIONAHA.117.09741","article-title":"Low soluble fms-like tyrosine kinase-1, endoglin, and endothelin-1 levels in women with confirmed or suspected preeclampsia using proton pump inhibitors","volume":"70","author":"Saleh","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.09.014_bib55","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1161\/HYPERTENSIONAHA.118.12547","article-title":"Proton pump inhibitors and preeclampsia risk among 157 720 women","volume":"73","author":"Hastie","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.09.014_bib56","doi-asserted-by":"crossref","first-page":"388.e1","DOI":"10.1016\/j.ajog.2018.07.019","article-title":"Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial","volume":"219","author":"Cluver","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.014_bib57","doi-asserted-by":"crossref","first-page":"356.e1","DOI":"10.1016\/j.ajog.2015.12.019","article-title":"Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction","volume":"214","author":"Brownfoot","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.014_bib58","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/fcp.12501","article-title":"Protective effect of metformin on a rat model of lipopolysaccharide-induced preeclampsia","volume":"33","author":"Hu","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.ajog.2020.09.014_bib59","doi-asserted-by":"crossref","first-page":"6547019","DOI":"10.1155\/2019\/6547019","article-title":"Effect of metformin on a preeclampsia-like mouse model induced by high-fat diet","volume":"2019","author":"Wang","year":"2019","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.ajog.2020.09.014_bib60","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1509819","article-title":"Metformin versus placebo in obese pregnant women without diabetes mellitus","volume":"374","author":"Syngelaki","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2020.09.014_bib61","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/dme.13523","article-title":"Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis","volume":"35","author":"Alqudah","year":"2018","journal-title":"Diabet Med"},{"key":"10.1016\/j.ajog.2020.09.014_bib62","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/jamapediatrics.2018.4214","article-title":"Association of long-term child growth and developmental outcomes with metformin vs insulin treatment for gestational diabetes","volume":"173","author":"Landi","year":"2019","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.ajog.2020.09.014_bib63","doi-asserted-by":"crossref","first-page":"367.e1","DOI":"10.1016\/j.ajog.2018.06.013","article-title":"A\u00a0cautionary response to SMFM statement: pharmacological treatment of gestational diabetes","volume":"219","author":"Barbour","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.014_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025809","article-title":"A\u00a0double blind, randomised, placebo-controlled trial to evaluate the efficacy of metformin to treat preterm pre-eclampsia (PI2 trial): study protocol","volume":"9","author":"Cluver","year":"2019","journal-title":"BMJ Open"},{"issue":"Suppl1","key":"10.1016\/j.ajog.2020.09.014_bib65","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.preghy.2018.08.287","article-title":"Clinical trial of metformin to treat preterm preeclampsia: pharmacokinetics and biomarker studies","volume":"13","author":"Tong","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.ajog.2020.09.014_bib66","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ebiom.2019.02.013","article-title":"Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction","volume":"41","author":"Brownfoot","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ajog.2020.09.014_bib67","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/HYPERTENSIONAHA.114.04781","article-title":"Sofalcone upregulates the nuclear factor (erythroid-derived 2)-like 2\/heme oxygenase-1 pathway, reduces soluble fms-like tyrosine kinase-1, and quenches endothelial dysfunction: potential therapeutic for preeclampsia","volume":"65","author":"Onda","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.09.014_bib68","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.mce.2015.06.033","article-title":"YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: a possible therapeutic for preeclampsia","volume":"413","author":"Brownfoot","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ajog.2020.09.014_bib69","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1096\/fj.14-252684","article-title":"Ouabain inhibits placental sFlt1 production by repressing HSP27-dependent HIF-1\u03b1 pathway","volume":"28","author":"Rana","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.ajog.2020.09.014_bib70","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/HYPERTENSIONAHA.118.12300","article-title":"EGFR (epidermal growth factor receptor) signaling and the mitochondria regulate sFlt-1 (soluble fms-like tyrosine kinase-1) secretion","volume":"73","author":"Hastie","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.09.014_bib71","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.placenta.2019.09.004","article-title":"Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling","volume":"87","author":"Hastie","year":"2019","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2020.09.014_bib72","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.106.660134","article-title":"Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1","volume":"115","author":"Cudmore","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ajog.2020.09.014_bib73","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.02242","article-title":"Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis","volume":"3","author":"Wheaton","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.ajog.2020.09.014_bib74","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2049-3002-2-12","article-title":"Metformin directly acts on mitochondria to alter cellular bioenergetics","volume":"2","author":"Andrzejewski","year":"2014","journal-title":"Cancer Metab"},{"key":"10.1016\/j.ajog.2020.09.014_bib75","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1200\/JCO.2009.25.7857","article-title":"Metformin, B(12), and enhanced breast cancer response to chemotherapy","volume":"28","author":"Garcia","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2020.09.014_bib76","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1056\/NEJMoa0908056","article-title":"Vitamins C and E to prevent complications of pregnancy-associated hypertension","volume":"362","author":"Roberts","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2020.09.014_bib77","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0140-6736(99)80010-5","article-title":"Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial","volume":"354","author":"Chappell","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2020.09.014_bib78","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12508","article-title":"Melatonin improves endothelial function in\u00a0vitro and prolongs pregnancy in women with early-onset preeclampsia","volume":"65","author":"Hobson","year":"2018","journal-title":"J\u00a0Pineal Res"},{"key":"10.1016\/j.ajog.2020.09.014_bib79","article-title":"The potent antioxidant MitoQ protects against preeclampsia during late gestation but increases the risk of preeclampsia when administered in early pregnancy","author":"Yang","year":"2020","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.ajog.2020.09.014_bib80","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/s41598-017-01993-w","article-title":"Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment","volume":"7","author":"Hannan","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajog.2020.09.014_bib81","doi-asserted-by":"crossref","first-page":"4154010","DOI":"10.1155\/2020\/4154010","article-title":"Resveratrol supplementation prevents hypertension in hypertensive pregnant rats by increasing sodium excretion and serum nitric oxide level","volume":"2020","author":"Jia","year":"2020","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.ajog.2020.09.014_bib82","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/10641955.2020.1754850","article-title":"A\u00e7ai (Euterpe oleracea Mart) seed extract protects against maternal vascular dysfunction, hypertension, and fetal growth restriction in experimental preeclampsia","volume":"39","author":"da Silva","year":"2020","journal-title":"Hypertens Pregnancy"},{"key":"10.1016\/j.ajog.2020.09.014_bib83","doi-asserted-by":"crossref","first-page":"110122","DOI":"10.1016\/j.biopha.2020.110122","article-title":"The bioflavonoid quercetin improves pathophysiology in a rat model of preeclampsia","volume":"127","author":"Li","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ajog.2020.09.014_bib84","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1161\/HYPERTENSIONAHA.119.13929","article-title":"L-(+)-ergothioneine significantly improves the clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model","volume":"75","author":"Williamson","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.09.014_bib85","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s12272-020-01220-7","article-title":"Mangiferin ameliorates placental oxidative stress and activates PI3K\/Akt\/mTOR pathway in mouse model of preeclampsia","volume":"43","author":"Huang","year":"2020","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.ajog.2020.09.014_bib86","doi-asserted-by":"crossref","first-page":"F366","DOI":"10.1152\/ajprenal.00501.2016","article-title":"Nicotinamide ameliorates a preeclampsia-like condition in mice with reduced uterine perfusion pressure","volume":"312","author":"Fushima","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ajog.2020.09.014_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preghy.2019.02.002","article-title":"Sulforaphane improves endothelial function and reduces placental oxidative stress in\u00a0vitro","volume":"16","author":"Cox","year":"2019","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.ajog.2020.09.014_bib88","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027493","article-title":"Prolong: a double-blind randomised placebo-controlled trial of broccoli sprout extract in women with early onset preeclampsia. A clinical trial protocol","volume":"9","author":"Langston-Cox","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.ajog.2020.09.014_bib89","doi-asserted-by":"crossref","first-page":"k3478","DOI":"10.1136\/bmj.k3478","article-title":"Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial","volume":"362","author":"Wen","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2020.09.014_bib90","doi-asserted-by":"crossref","first-page":"13450","DOI":"10.1073\/pnas.1614947113","article-title":"Nicotinamide benefits both mothers and pups in two contrasting mouse models of preeclampsia","volume":"113","author":"Li","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ajog.2020.09.014_bib91","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/AOG.0000000000001518","article-title":"Perinatal and hemodynamic evaluation of sildenafil citrate for preeclampsia treatment: a randomized controlled trial","volume":"128","author":"Trapani","year":"2016","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.014_bib92","doi-asserted-by":"crossref","first-page":"k3247","DOI":"10.1136\/bmj.k3247","article-title":"Trial of Viagra for fetal growth restriction is halted after baby deaths","volume":"362","author":"Hawkes","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2020.09.014_bib93","doi-asserted-by":"crossref","first-page":"d2901","DOI":"10.1136\/bmj.d2901","article-title":"Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial","volume":"342","author":"Vadillo-Ortega","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2020.09.014_bib94","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/10641955.2015.1137586","article-title":"Efficacy of L-arginine for preventing preeclampsia in high-risk pregnancies: a double-blind, randomized, clinical trial","volume":"35","author":"Camarena Pulido","year":"2016","journal-title":"Hypertens Pregnancy"},{"key":"10.1016\/j.ajog.2020.09.014_bib95","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.pathophys.2018.08.001","article-title":"L-arginine attenuates blood pressure and reverses the suppression of angiogenic risk factors in a rat model of preeclampsia","volume":"25","author":"Oludare","year":"2018","journal-title":"Pathophysiology"},{"key":"10.1016\/j.ajog.2020.09.014_bib96","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.pathophys.2019.02.002","article-title":"L-arginine supplementation lowers blood pressure, protein excretion and plasma lipid profile in experimental salt-induced hypertension in pregnancy: relevance to preeclampsia","volume":"26","author":"Arikawe","year":"2019","journal-title":"Pathophysiology"},{"key":"10.1016\/j.ajog.2020.09.014_bib97","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bcp.12379","article-title":"S-nitrosoglutathione improves haemodynamics in early-onset pre-eclampsia","volume":"78","author":"Everett","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl2","key":"10.1016\/j.ajog.2020.09.014_bib98","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s13224-018-1100-1","article-title":"Nitric oxide in the prevention of pre-eclampsia (NOPE): a double-blind randomized placebo-controlled trial assessing the efficacy of isosorbide mononitrate in the prevention of pre-eclampsia in high-risk women","volume":"69","author":"Ponmozhi","year":"2019","journal-title":"J\u00a0Obstet Gynaecol India"},{"key":"10.1016\/j.ajog.2020.09.014_bib99","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/biolre\/iox023","article-title":"Relaxin treatment reduces angiotensin II-induced vasoconstriction in pregnancy and protects against endothelial dysfunction","volume":"96","author":"Marshall","year":"2017","journal-title":"Biol Reprod"},{"key":"10.1016\/j.ajog.2020.09.014_bib100","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1210\/jc.2002-021160","article-title":"Triglyceride-rich lipoproteins are associated with hypertension in preeclampsia","volume":"88","author":"Winkler","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ajog.2020.09.014_bib101","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.transci.2006.05.010","article-title":"Heparin-mediated extracorporeal low density lipoprotein precipitation as a possible therapeutic approach in preeclampsia","volume":"35","author":"Wang","year":"2006","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.ajog.2020.09.014_bib102","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1161\/CIRCULATIONAHA.111.034793","article-title":"Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia","volume":"124","author":"Thadhani","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ajog.2020.09.014_bib103","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1681\/ASN.2015020157","article-title":"Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia","volume":"27","author":"Thadhani","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ajog.2020.09.014_bib104","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/tog.12254","article-title":"The role of transabdominal cervical cerclage techniques in maternity care","volume":"18","author":"Gibb","year":"2016","journal-title":"Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2020.09.014_bib105","doi-asserted-by":"crossref","first-page":"R1425","DOI":"10.1152\/ajpregu.00372.2015","article-title":"Placental ischemia-induced increases in brain water content and cerebrovascular permeability: role of TNF-\u03b1","volume":"309","author":"Warrington","year":"2015","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.ajog.2020.09.014_bib106","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/HJH.0b013e3283468392","article-title":"Changes in cardiac structure in hypertension produced by placental ischemia in pregnant rats: effect of tumor necrosis factor blockade","volume":"29","author":"Gutkowska","year":"2011","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ajog.2020.09.014_bib107","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11906-017-0784-4","article-title":"The complement system and preeclampsia","volume":"19","author":"Regal","year":"2017","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.ajog.2020.09.014_bib108","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.placenta.2012.11.014","article-title":"Eculizumab for the treatment of preeclampsia\/HELLP syndrome","volume":"34","author":"Burwick","year":"2013","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2020.09.014_bib109","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-228709","article-title":"Eculizumab, a novel potential treatment for acute kidney injury associated with preeclampsia\/HELLP syndrome","volume":"12","author":"Elabd","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ajog.2020.09.014_bib110","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3389\/fimmu.2020.00548","article-title":"Eculizumab treatment for postpartum HELLP syndrome and aHUS-case report","volume":"11","author":"Lokki","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajog.2020.09.014_bib111","doi-asserted-by":"crossref","first-page":"119.e1","DOI":"10.1016\/j.ajog.2013.04.010","article-title":"Digoxin antibody fragment, antigen binding (Fab), treatment of preeclampsia in women with endogenous digitals-like factor: a secondary analysis of the DEEP Trial","volume":"209","author":"Lam","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.014_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2020.08.004","article-title":"Prospective, randomized, double-blind, placebo-controlled evaluation of the pharmacokinetics, safety and efficacy of recombinant antithrombin versus placebo in preterm preeclampsia","author":"Paidas","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.014_bib113","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1161\/HYPERTENSIONAHA.116.07286","article-title":"Placental growth factor reduces blood pressure in a uteroplacental ischemia model of preeclampsia in nonhuman primates","volume":"67","author":"Makris","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.09.014_bib114","doi-asserted-by":"crossref","DOI":"10.1038\/nbt.4297","article-title":"RNAi modulation of placental sFLT1 for the treatment of preeclampsia","author":"Turanov","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ajog.2020.09.014_bib115","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1172\/JCI99417","article-title":"RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models","volume":"130","author":"Haase","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ajog.2020.09.014_bib116","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.semnephrol.2010.10.005","article-title":"Renin angiotensin signaling in normal pregnancy and preeclampsia","volume":"31","author":"Irani","year":"2011","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ajog.2020.09.014_bib117","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11906-020-1034-8","article-title":"Emerging therapeutic potential of mesenchymal stem\/stromal cells in preeclampsia","volume":"22","author":"Suvakov","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.ajog.2020.09.014_bib118","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fbioe.2020.00064","article-title":"Trophoblast-targeted nanomedicine modulates placental sFLT1 for preeclampsia treatment","volume":"8","author":"Li","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.ajog.2020.09.014_bib119","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/HYPERTENSIONAHA.119.13368","article-title":"Biopolymer-delivered, maternally sequestered NF-\u03baB (nuclear factor-\u03baB) inhibitory peptide for treatment of preeclampsia","volume":"75","author":"Eddy","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.09.014_bib120","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/uog.19039","article-title":"Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE","volume":"51","author":"Tan","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.014_bib121","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.tips.2013.06.005","article-title":"Cancer drug discovery by repurposing: teaching new tricks to old dogs","volume":"34","author":"Gupta","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.ajog.2020.09.014_bib122","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13046-019-1094-2","article-title":"Clinical development of targeted\u00a0and immune based anti-cancer therapies","volume":"38","author":"Seebacher","year":"2019","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.ajog.2020.09.014_bib123","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ajog.2020.09.014_bib124","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937820310711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937820310711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:34:19Z","timestamp":1757590459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937820310711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0002937820310711"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2020.09.014","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2020.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}